PI-042 - AREAS OF CLINICAL RELEVANCE AND PHARMACOGENE ACTIONABILITY FOR PATIENTS FROM A PHARMACIST-LED, VIRTUAL PHARMACOGENETICS CONSULTATION CLINIC.

M. Norris¹, E. Eddy², I. Fofanova², K. Wiisanen², J. Gums³, E. Cicali⁴; ¹University of Florida., Gainesville, FL, United States, ²Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida., Gainesville, FL, United States, ³Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, United States, ⁴University of Florida, Gainesville, FL, United States.

Background: The University of Florida Health Precision Medicine Program’s (PMP) pharmacist-led pharmacogenetics (PGx) consultation clinic, MyRx, launched in 2022. MyRx aims to expand the reach of UF’s PGx program by offering a virtual service. While marketing efforts focus on psychiatry, relevant clinical areas covered by the pharmacist and pharmacogene results within MyRx’s patient population have yet to be assessed. The purpose of this project is to summarize observed trends.

Methods: Patients are referred to MyRx by their provider, self-initiated contact, or upon completion of in-house panel-based PGx testing. If needed, MyRx coordinates testing through an in-person lab draw or mailed cheek swab kit. Once PGx results are received, either from the patient or internal lab, their virtual consultation is scheduled. Patient demographics, referral method/reason, and registration trends are tracked for clinical purposes. Following the educational consultation, relevant clinical areas covered (e.g., those in which the patient is on or planning to start a relevant medication) are documented, regardless of the initial reason for referral. For the purpose of this analysis, genes relevant to clinical areas were assessed for prevalence of potentially actionable phenotypes (i.e., recommendation made) as follows: Psychiatry, CYP2D6 and CYP2C19; Cardiology, SLCO1B1 and CYP2C19; Gastrointestinal (GI), CYP2C19; Pain, CYP2D6 and CYP2C9. Actionable phenotype prevalence were compared to a European reference population using Fisher’s Exact Test.

Results: To date, 216 patients have been seen for a consultation. Of those with demographics available, the majority were female (66%) and White/European (90%). The majority (69%) of patients had > 1 relevant clinical area (median = 2 ± 1), and 39% had > 2. The most common was psychiatry, followed by pain, GI, then cardiology. Prevalence of observed actionable phenotypes were not statistically different than expected, although they are trending higher. Overall, 85% of psychiatry, 47% of cardiology, and 37% of pain patients had ≥ 1 relevant gene with an actionable phenotype.

Conclusion: Psychiatry is the most common clinical area for PGx consultation, followed by pain and GI. Most patients have multiple relevant clinical areas, and a high percentage of actionable phenotypes. This supports the value of PGx consultation.